Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study

<p>Abstract</p> <p>Objectives</p> <p>Prolonged postoperative air leaks (AL) are a major cause of morbidity. Aim of this work was evaluating use of a Lung Sealant System (Pleuraseal™, Covidien, Mansfield, MA, U.S.A.) in pleural decortications for empyema thoracis.</p&...

Full description

Bibliographic Details
Main Authors: Lybéris Paraskevas, Bertolaccini Luca, Manno Emilpaolo
Format: Article
Language:English
Published: BMC 2010-05-01
Series:Journal of Cardiothoracic Surgery
Online Access:http://www.cardiothoracicsurgery.org/content/5/1/45
id doaj-61b226c08657472bb7ecc1f890c45d88
record_format Article
spelling doaj-61b226c08657472bb7ecc1f890c45d882020-11-24T21:12:04ZengBMCJournal of Cardiothoracic Surgery1749-80902010-05-01514510.1186/1749-8090-5-45Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded studyLybéris ParaskevasBertolaccini LucaManno Emilpaolo<p>Abstract</p> <p>Objectives</p> <p>Prolonged postoperative air leaks (AL) are a major cause of morbidity. Aim of this work was evaluating use of a Lung Sealant System (Pleuraseal™, Covidien, Mansfield, MA, U.S.A.) in pleural decortications for empyema thoracis.</p> <p>Methods</p> <p>From January 2008 to December 2008, 46 consecutive patients received pleural decortications for empyema thoracis. Post-procedural and malignancy-related empyemas were excluded. After hydro-pneumatic test and surgical correction of AL (until satisfaction), patients were assigned (23 per group) to Control or Sealant group. Control group underwent no additional interventions. In Sealant group, lung sealant was applied over AL areas. Following variables were measured daily: patients with AL; time to chest drainage (CD) removal; CD drainage volume at removal, postoperative length of hospital stay, postoperative C-reactive protein (CRP), and leukocyte counts. Personnel recording parameters were blinded to intervention. Two-tailed t-tests (normally distributed data) or Mann - Whitney U-test (not-normally distributed data) were used for evaluating significance of differences between group means or medians. Significance of any proportional differences in attributes were evaluated using Fisher's Exact Test. Statistical analysis was carried out using R-software (version 2.8.1).</p> <p>Results</p> <p>Groups were similar regarding demographic and baseline characteristics. No patients were withdrawn from study; no adverse effects were recorded. There were no significative differences on CRP and leukocyte levels between two groups. Compared with the Control group, in Sealant group significantly fewer patients had AL (30 versus 78%, <it>p = 0.012</it>), and drains were inserted for a shorter time (medians, 3 versus 5 days, <it>p = 0.05</it>). Postoperative hospitalization time was shorter in Sealant group than in control group, but difference was not significant (0.7 days, <it>p = 0.121</it>).</p> <p>Conclusions</p> <p>Pleuraseal™ Lung Sealant System significantly reduces AL following pleural decortications for empyema and, despite of not-increased infectious indexes, is suitable for routinely use, even in procedures with contaminated pleura.</p> http://www.cardiothoracicsurgery.org/content/5/1/45
collection DOAJ
language English
format Article
sources DOAJ
author Lybéris Paraskevas
Bertolaccini Luca
Manno Emilpaolo
spellingShingle Lybéris Paraskevas
Bertolaccini Luca
Manno Emilpaolo
Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study
Journal of Cardiothoracic Surgery
author_facet Lybéris Paraskevas
Bertolaccini Luca
Manno Emilpaolo
author_sort Lybéris Paraskevas
title Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study
title_short Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study
title_full Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study
title_fullStr Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study
title_full_unstemmed Lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study
title_sort lung sealant and morbidity after pleural decortication: a prospective randomized, blinded study
publisher BMC
series Journal of Cardiothoracic Surgery
issn 1749-8090
publishDate 2010-05-01
description <p>Abstract</p> <p>Objectives</p> <p>Prolonged postoperative air leaks (AL) are a major cause of morbidity. Aim of this work was evaluating use of a Lung Sealant System (Pleuraseal™, Covidien, Mansfield, MA, U.S.A.) in pleural decortications for empyema thoracis.</p> <p>Methods</p> <p>From January 2008 to December 2008, 46 consecutive patients received pleural decortications for empyema thoracis. Post-procedural and malignancy-related empyemas were excluded. After hydro-pneumatic test and surgical correction of AL (until satisfaction), patients were assigned (23 per group) to Control or Sealant group. Control group underwent no additional interventions. In Sealant group, lung sealant was applied over AL areas. Following variables were measured daily: patients with AL; time to chest drainage (CD) removal; CD drainage volume at removal, postoperative length of hospital stay, postoperative C-reactive protein (CRP), and leukocyte counts. Personnel recording parameters were blinded to intervention. Two-tailed t-tests (normally distributed data) or Mann - Whitney U-test (not-normally distributed data) were used for evaluating significance of differences between group means or medians. Significance of any proportional differences in attributes were evaluated using Fisher's Exact Test. Statistical analysis was carried out using R-software (version 2.8.1).</p> <p>Results</p> <p>Groups were similar regarding demographic and baseline characteristics. No patients were withdrawn from study; no adverse effects were recorded. There were no significative differences on CRP and leukocyte levels between two groups. Compared with the Control group, in Sealant group significantly fewer patients had AL (30 versus 78%, <it>p = 0.012</it>), and drains were inserted for a shorter time (medians, 3 versus 5 days, <it>p = 0.05</it>). Postoperative hospitalization time was shorter in Sealant group than in control group, but difference was not significant (0.7 days, <it>p = 0.121</it>).</p> <p>Conclusions</p> <p>Pleuraseal™ Lung Sealant System significantly reduces AL following pleural decortications for empyema and, despite of not-increased infectious indexes, is suitable for routinely use, even in procedures with contaminated pleura.</p>
url http://www.cardiothoracicsurgery.org/content/5/1/45
work_keys_str_mv AT lyberisparaskevas lungsealantandmorbidityafterpleuraldecorticationaprospectiverandomizedblindedstudy
AT bertolacciniluca lungsealantandmorbidityafterpleuraldecorticationaprospectiverandomizedblindedstudy
AT mannoemilpaolo lungsealantandmorbidityafterpleuraldecorticationaprospectiverandomizedblindedstudy
_version_ 1716751593746989056